← Back to Search

Neurotoxin

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Phase 3
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 371 days (from enrollment in the lead-in study m21-309 through end of study m21-323)
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing whether Botox is safe for adults with a certain kind of neck muscle issue.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~371 days (from enrollment in the lead-in study m21-309 through end of study m21-323)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 371 days (from enrollment in the lead-in study m21-309 through end of study m21-323) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Adverse Events

Side effects data

From 2014 Phase 4 trial • 250 Patients • NCT02096081
6%
Headache
2%
Facial Asymmetry
1%
Human ehrlichiosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
IncobotulinumtoxinA
OnabotulinumtoxinA

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BOTOXExperimental Treatment1 Intervention
BOTOX (OnabotulinumtoxinA) will be injected into the platysma muscle for up to 3 Cycles during study M21-323
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OnabotulinumtoxinA
2014
Completed Phase 4
~3600

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
1,037 Previous Clinical Trials
522,652 Total Patients Enrolled
AllerganLead Sponsor
781 Previous Clinical Trials
276,393 Total Patients Enrolled
ALLERGAN INC.Study DirectorAllergan
75 Previous Clinical Trials
79,283 Total Patients Enrolled
~73 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top